Author + information
- Received October 8, 2008
- Accepted October 31, 2008
- Published online March 1, 2009.
- Andrew J. Einstein, MD, PhD, FACC⁎ ()
- ↵⁎Reprint requests and correspondence to:
Dr. Andrew J. Einstein, Columbia University Medical Center, 622 West 168th Street, PH 10-203A, New York, New York 10032
Approximately 9 million nuclear cardiology studies performed each year in the U.S. use technetium-99m, which is produced from the decay of molybdenum-99. The fragility of the worldwide technetium-99m supply chain has been underscored by current shortages caused by an unplanned shutdown of Europe's largest reactor. The majority of the U.S. supply derives from a reactor in Canada that is nearing the end of its lifespan and whose planned replacements have been cancelled recently. In this article, the clinical importance of technetium-99m and our tenuous dependence on the foreign supply of molybdenum are addressed, along with potential measures that may be taken to ensure that America's supply chain remains unbroken.
Dr. Einstein is supported in part by an NIH K12 institutional career development award (5 KL2 RR024157-03). Dr. Einstein reports receiving an American Society of Nuclear Cardiology/Nuclear Cardiology Foundation research grant that was sponsored by Covidien (Covidien's support was only disclosed to Dr. Einstein after receiving the grant), consulting fees from GE Healthcare (unrelated to GE's SPECT, PET or radiopharmaceutical units), and travel expenses covered by GE Healthcare, INVIA, Philips Medical Systems, and Toshiba America Medical Systems.
- Received October 8, 2008.
- Accepted October 31, 2008.
- American College of Cardiology Foundation